Daré Bioscience, Inc. (DARE)

Daré Bioscience Statistics

Total Valuation

Daré Bioscience has a market cap or net worth of $25.33 million. The enterprise value is $3.28 million.

Market Cap	25.33M
Enterprise Value	3.28M

Important Dates

The next estimated earnings date is Tuesday, May 12, 2026, after market close.

Earnings Date	May 12, 2026
Ex-Dividend Date	n/a

Share Statistics

Daré Bioscience has 14.56 million shares outstanding. The number of shares has increased by 31.55% in one year.

Current Share Class	14.56M
Shares Outstanding	14.56M
Shares Change (YoY)	+31.55%
Shares Change (QoQ)	+12.00%
Owned by Insiders (%)	0.95%
Owned by Institutions (%)	8.42%
Float	13.31M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	24.59
Forward PS	0.86
PB Ratio	8.88
P/TBV Ratio	8.91
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	3.18
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 1.14, with a Debt / Equity ratio of 0.93.

Current Ratio	1.14
Quick Ratio	1.07
Debt / Equity	0.93
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	n/a

Financial Efficiency

Return on Equity (ROE)	n/a
Return on Assets (ROA)	-31.04%
Return on Invested Capital (ROIC)	-2,145.49%
Return on Capital Employed (ROCE)	-154.20%
Weighted Average Cost of Capital (WACC)	8.33%
Revenue Per Employee	$44,791
Profits Per Employee	-$582,577
Employee Count	23
Asset Turnover	0.04
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -40.00% in the last 52 weeks. The beta is 0.90, so Daré Bioscience's price volatility has been lower than the market average.

Beta (5Y)	0.90
52-Week Price Change	-40.00%
50-Day Moving Average	1.65
200-Day Moving Average	2.02
Relative Strength Index (RSI)	58.63
Average Volume (20 Days)	106,402

Short Selling Information

The latest short interest is 214,286, so 1.47% of the outstanding shares have been sold short.

Short Interest	214,286
Short Previous Month	290,470
Short % of Shares Out	1.47%
Short % of Float	1.61%
Short Ratio (days to cover)	2.99

Income Statement

In the last 12 months, Daré Bioscience had revenue of $1.03 million and -$13.40 million in losses. Loss per share was -$1.20.

Revenue	1.03M
Gross Profit	734,394
Operating Income	-13.55M
Pretax Income	-13.40M
Net Income	-13.40M
EBITDA	-11.92M
EBIT	-13.55M
Loss Per Share	-$1.20

Balance Sheet

The company has $24.71 million in cash and $2.66 million in debt, with a net cash position of $22.06 million or $1.51 per share.

Cash & Cash Equivalents	24.71M
Total Debt	2.66M
Net Cash	22.06M
Net Cash Per Share	$1.51
Equity (Book Value)	2.84M
Book Value Per Share	0.20
Working Capital	3.38M

Cash Flow

In the last 12 months, operating cash flow was -$9.89 million and capital expenditures -$385,278, giving a free cash flow of -$10.27 million.

Operating Cash Flow	-9.89M
Capital Expenditures	-385,278
Depreciation & Amortization	1.63M
Net Borrowing	-1.33M
Free Cash Flow	-10.27M
FCF Per Share	-$0.71

Margins

Gross Margin	71.29%
Operating Margin	-1,315.51%
Pretax Margin	-1,300.66%
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

Daré Bioscience does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-31.55%
Shareholder Yield	-31.55%
Earnings Yield	-52.89%
FCF Yield	-40.54%

Analyst Forecast

The average price target for Daré Bioscience is $10.00, which is 474.71% higher than the current price. The consensus rating is "Strong Buy".

Price Target	$10.00
Price Target Difference	474.71%
Analyst Consensus	Strong Buy
Analyst Count	2
Revenue Growth Forecast (5Y)	232.60%
EPS Growth Forecast (5Y)	n/a

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

The last stock split was on July 1, 2024. It was a reverse split with a ratio of 1:12.

Last Split Date	Jul 1, 2024
Split Type	Reverse
Split Ratio	1:12

Scores

Daré Bioscience has an Altman Z-Score of -8.82 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-8.82
Piotroski F-Score	2